+44 (0) 20 7549 9987 | USA callers: 00-1-718-682-4567

Contact Us Now

World Cancer-Treating Drugs Market Set To Grow To $152bn By 2022

10 August 2018
Pharma

Visiongain has launched a new pharma report World Cancer-Treating Drugs Market Forecast 2017-2027: Immunotherapy, Chemotherapy, Targeted Therapy, Hormone Therapy, Leading Drugs

The future of the anti-cancer drugs market looks promising, as a number of new and innovative therapies are coming on to the market. In recent years there has been a remarkable improvement in the safety of products, with improvements of delivery of chemotherapy, among other techniques, reducing the toxicity of treatments.

The lead analyst of the report commented “’The anti-cancer treatments market will see strong growth driven by the ageing population, increasing demand of biological and targeted drug therapies, continuous patent expiry of major cancer drugs with generic competition eroding their share of the market and the rising uptake of biosimilars.

The anti-cancer drugs pipeline includes monoclonal antibodies, new classes of novel antineoplastics (including PARP inhibitors) and therapeutic vaccines. The launch of emerging classes, including immuno-oncologics, and combination therapies will offer potential breakthrough in cancer treatment. On a global context, the US will remain the largest market while emerging markets will see the highest rate of growth”

Leading companies featured in the report include AstraZeneca, Merck & Co., Inc. (Merck), Novartis, Amgen, Bristol-Myers Squibb (BMS), GlaxoSmithKline (GSK), Johnson & Johnson (J&J), Roche, Eli Lilly and Celgene.

Notes for Editors
If you are interested in a more detailed overview of this report, please send an e-mail to sara.peerun@visiongainglobal.com or call her on +44 (0) 207 336 6100

About visiongain
Visiongain is one of the fastest-growing and most innovative independent media companies in Europe. Based in London, UK, visiongain produces a host of business-to-business reports cusing on the automotive, aviation, chemicals, cyber, defence, energy, food & drink, materials, packaging, pharmaceutical and utilities sectors.

Visiongain publishes reports produced by analysts who are qualified experts in their field. Visiongain has firmly established itself as the first port of call for the business professional who needs independent, high-quality, original material to rely and depend on.

Recent News

Visiongain Publishes Gene Amplification Technologies Market Report 2023-2033

The Gene Amplification Technologies market was valued at US$4,587 million in 2022 and is projected to grow at a CAGR of 9.8% during the forecast period 2023-2033.

05 December 2022

Read

Visiongain Publishes Stem Cell Technologies and Applications Market Report 2022-2032

The global stem cell technologies and applications market was valued at US$9,247 million in 2021 and is projected to grow at a CAGR of 8.9% during the forecast period 2022-2032.

01 December 2022

Read

Visiongain Publishes Biosimilars and Follow-On Biologics Market Report 2023-2033

The biosimilars and follow-on biologics market is valued at US$19,668.3 million in 2022 and is projected to grow at a CAGR of 31.14% during the forecast period 2023-2033.

01 December 2022

Read

Visiongain Publishes Medical Imaging Market Report 2022-2032

The Medical Imaging market was valued at US$38.6 billion in 2021 and is projected to grow at a CAGR of 5.46% during the forecast period 2022-2032.

30 November 2022

Read

Kelloggs
3m
Thales
Shell
TEVA
Lockheed-Martin
Pfizer
Raytheon
Halliburton
Du-Pont
Honeywell
Daimler
BASF
Bayer
BP
BAE-Systems
Unilever